Navigation Links
PharmAthene Reports Third Quarter 2011 Financial and Operating Results
Date:11/9/2011

g which the Court will render its final order.  We look forward to a resolution of these next steps and to SIGA's successful commercialization of ST-246, which has the opportunity for additional U.S. government procurement contracts."

Third Quarter Financial ResultsFor the third quarter of 2011 PharmAthene recognized revenue of $5.3 million compared to $6.2 million in the same period of 2010.  Revenues for the most recent quarter consisted of contract funding from the U.S. government for the development of the Company's SparVax™ and Valortim® biodefense programs.  

Revenues for the Company's SparVax™ program were $4.3 million for the three months ended September 30, 2011 compared to $3.8 million for the same period in 2010.  The increase in revenue for the Company's SparVax™ program is primarily attributable to additional work conducted in relation to the technology transfer process for SparVax™ to a US-based contract manufacturer and related milestone payments.

Revenues for the Company's Valortim® program were $0.9 million for the third quarter of 2011 compared to $0.6 million for the same period in 2010. The increase in revenues for SparVax™ and Valortim® during this period was offset by a decrease in Protexia® revenue resulting from the completion of PharmAthene's contract with the Department of Defense (DoD) in 2010.

Research and development expenses were $4.9 million for the quarter ended September 30, 2011 compared to $6.2 million for the same period in 2010.  The year-over-year difference in research and development expenses were primarily due to the decrease in development expenses related to the completion of the bioscavenger contract with the DoD.

General and administrative expenses were $3.3 million and $3.2 million for the quarters ended September 30, 2011 and 2010, respectively.

For the third quarter of 2011 PharmAthene's net loss att
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
2. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
3. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
4. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
5. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
6. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
7. PharmAthene Completes $6.5 Million Registered Direct Offering
8. PharmAthene Reports First Quarter 2011 Financial and Operating Results
9. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
10. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/53wxp3/israel_biomedical ) has ... Market - Growth, Trends & Forecasts (2014-2020)" report ... Sensors market is estimated at $0.19 billion by 2018 ... The near future will bring biomedical sensors ... individual. These sensors can be set to trigger alerts ...
(Date:8/31/2015)... SYDNEY , Aug. 31, 2015  US-Australian ... NVGN ) today confirmed its comprehensive scientific ... ground-breaking technology platforms in areas of unmet patient ... through the remaining preclinical projects prior to entering ... lead compounds. Acting Chief Executive Officer, ...
(Date:8/31/2015)... Grove, IL (PRWEB) , ... August 31, 2015 ... ... impurities (PGIs), as a high priority in the drug development approval process. Thus, ... , This year, Regis Technologies, Inc., a Chicago-based CMO, has been hosting ...
(Date:8/28/2015)... Aug. 28, 2015 Research ... of the "Global & USA BioSimilar Market Analysis ... The highly awaited US Biosimilar market will be initiated ... biologic, Zarxio. How will the global market react? Will ... that biosimilars could save the US economy up to ...
Breaking Biology Technology:Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3
... 14 at 8:00 a.m. PDT ... ... (Nasdaq: HALO ), a biopharmaceutical company developing and,commercializing products targeting the ... December 31, 2007., "Our achievements in 2007 have advanced our partnered ...
... (NASDAQ: ANPI , TSX: ANP), a global ... filing of its audited,consolidated financial statements and Management,s ... 2007 and the restatement of its audited,consolidated financial ... For the year ended December 31, 2007, ...
... CORONA, Calif., March 13 Watson,Pharmaceuticals, Inc. ... today confirmed that it has filed an Abbreviated ... Drug Administration (FDA) seeking,approval to market its Levonorgestrel ... oral contraceptive product prior to the,expiration of patents ...
Cached Biology Technology:Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 2Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 3Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 4Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 5Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 6Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 7Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 8Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 2Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 3Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 4Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 5Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 6Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 7Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 8Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 9Watson Files FDA Application for Generic LYBREL(R) 2
(Date:8/20/2015)... 2015   Sensory, Inc ., a Silicon ... experience and security of consumer electronics through state-of-the-art ... its TrulySecure™ is the first multimodal ... FIDO Certified™. The FIDO (Fast Identification ... FIDO UAF (Universal Authentication Framework) 1.0 specifications, which ...
(Date:8/17/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 2015. The new marketing campaign is being spearheaded by ... Group ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ). ... retail driven marketing and brand awareness and has a ...
(Date:8/11/2015)... , August 11, 2015 Today, ZUK announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a prominent smartphone manufacturer in ... selected FPC1 155 for ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... Picture two charged particles in a vacuum. Thanks to ... force these particles exert upon one another, and therefore ... simple medium say, water and the calculation ... water, which in turn may slow, speed, or otherwise ...
... the unique aroma signature of the durian revered as ... as the world,s foulest smelling food has uncovered several ... in ACS, Journal of Agricultural and Food Chemistry . ... Asian food shops in the United States and elsewhere, has ...
... believe that fish ear bones and their distinctive growth rings ... in aquatic environments., The earbones, or ,otoliths, help fish to ... set down annual growth rings that can be measured and ... "Otoliths can form the basis of new techniques for ...
Cached Biology News:Outside a vacuum: Model predicts movement of charged particles in complex media 2Fish ear bones point to climate impacts 2
... The Beacon 2000 Fluorescence Polarization System ... research and assay development. Standard Beacon ... 2000 System uses a quartz-halogen lamp ... of 360-700 nm. It accommodates all ...
Preparation Note: Prepared essentially by method of Singer, T.P., J. Biol. Chem., 174, 11 (1948). Quality Clarifier: Contains lipase Unit Definition: One unit will hydrolyze 1.0 μmole of p-ni...
... buffer, pH 10.2 give activity approx. 2X ... in diethanolamine buffer, pH 9.8 give activity ... system. Protein determined by Biuret Physical form: ... Unit Definition: One unit will hydrolyze 1 ...
... traps a wide variety of solvent vapors that can ... flask (GCF400) allows for the collection of liquid into ... time minimizes waiting period., Ultra low -104 ... , Digital Display of ...
Biology Products: